Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Unknown 1Recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2Dermatologic 2Other hematologic neoplasm 1

Conditions

Lymphoma, T-Cell, Cutaneous 11Sezary Syndrome 3Mycosis Fungoides 3Recurrence 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell 1

Interventions

Peripheral Blood Stem Cell Transplantation 23fludarabine phosphate 20Cyclophosphamide 18Mycophenolic Acid 16Whole-Body Irradiation 15Cyclosporine 15Busulfan 12Tacrolimus 11Methotrexate 10Antilymphocyte Serum 9Radiotherapy 8Melphalan 8Etoposide 8pembrolizumab 7Methylprednisolone 6Filgrastim 6Sirolimus 4Prednisone 4Nivolumab 4sargramostim 3Vincristine 3Transplantation 3Therapeutics 3Polymerase Chain Reaction 3Cord Blood Stem Cell Transplantation 3Amplified Fragment Length Polymorphism Analysis 3mogamulizumab 2merphos 2bempegaldesleukin 2Voriconazole 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recurrence × mogamulizumab × Dermatologic × Clear all
NCT05996185 2026-04-14

Study of Mogamulizumab With DA-EPOCH or CHOEP in Patients With Aggressive T-cell Lymphoma

Yale University

Phase 2 Recruiting
22 enrolled
DermatologicLymphoidOther hematologic neoplasm

Recurrence, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT04745234 2024-04-25

Mogamulizumab Q4week Dosing in Participants With R/R CTCL

Kyowa Kirin Co., Ltd.

Phase 2 Unknown
34 enrolled
DermatologicLymphoid

Recurrence, Lymphoma, T-Cell, Cutaneous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡